- Business
- Tianjin Development Holdings Limited is a Hong Kong-listed investment holding company and conglomerate principally engaged in the supply of electricity, water, heat, and thermal power to industrial, commercial, and residential customers primarily in the Tianjin Economic and Technological Development Area of the People's Republic of China. The company operates through six main segments: the Utilities segment distributes electricity with an installed transmission capacity of approximately 996,000 kVA, water with a daily supply capacity of 325,000 tonnes, heat, and thermal power via approximately 549 kilometres of steam transmission pipelines, 120 processing stations, and a daily steam distribution capacity of 30,000 tonnes; the Pharmaceutical segment manufactures and sells chemical drugs, proprietary Chinese medicines, and other healthcare products, while providing pharmaceutical research and development services, as well as design, manufacture, and printing for pharmaceutical packaging; the Hotel segment manages hotel operations, including the Courtyard Hotel by Marriott Hong Kong; the Electrical and Mechanical segment manufactures and sells presses, mechanical and hydroelectric equipment, and large-scale pump units; the Port Services segment, contributed through equity-method accounted listed associate Tianjin Port Development Holdings Limited, provides container and cargo handling services; and the Elevators and Escalators segment, via equity-method investment in Otis Elevator (China) Investment Company Limited, manufactures and sells elevators and escalators. Additional activities encompass construction of electricity supply networks, new and renewable energy technology applications, electricity technical services, energy storage, water pipe installation and maintenance, technical consultancy, retail and wholesale of water pipes and parts, water testing services, and finance leasing. Founded on 9 May 1997 and headquartered at Suites 7-13, 36th Floor, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong, the company employs approximately 2,740 people and primarily generates revenue from the People's Republic of China, with minor operations in Hong Kong; it functions as a red chip subsidiary of state-owned Tianjin Pharmaceutical Group Co., Ltd. Recent developments include the acquisition of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. and its subsidiary during the six months ended 30 June 2024 to bolster pharmaceutical capabilities, alongside property, plant, and equipment additions of HK$25.9 million in the first half of 2025 and HK$63.7 million in the prior period for business expansion; in September 2025, a unit entered a partnership to establish a RMB500 million fund; and the company scheduled virtual extraordinary general meetings in October 2025 for 13 November approval and on 30 December 2024 of a Partnership Agreement and new fund formation to drive strategic operations.